GRIFTATIN Trademark

Trademark Overview


On Sunday, December 31, 2017, a trademark application was filed for GRIFTATIN with the United States Patent and Trademark Office. The USPTO has given the GRIFTATIN trademark a serial number of 87739250. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 26, 2021. This trademark is owned by Sentar Pharmaceuticals. The GRIFTATIN trademark is filed in the Pharmaceutical Products category with the following description:

Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of orodispersable tablets and/or sublingual tablets that facilitate the delivery of pharmaceutical preparations; Nutraceuticals for use as a dietary supplement; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical pr...
griftatin

General Information


Serial Number87739250
Word MarkGRIFTATIN
Filing DateSunday, December 31, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 26, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 24, 2018

Trademark Statements


Goods and ServicesDrug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of orodispersable tablets and/or sublingual tablets that facilitate the delivery of pharmaceutical preparations; Nutraceuticals for use as a dietary supplement; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of the cardiovascular system, the circulatory system, the digestive system, the excretory system, the endocrine system, the integumentary system, the exocrine system, the lymphatic system, the immune system, the muscular system, the nervous system, the renal system, the urinary system, the reproductive system, and/or the skeletal system; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Cardiovascular pharmaceuticals; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment of the endocannabinoid; Human vaccine preparations; Oral vaccine preparations

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 16, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSentar Pharmaceuticals
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIrvine, CA 92614

Party NameSentar Pharmaceuticals
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92614

Trademark Events


Event DateEvent Description
Monday, July 26, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 26, 2021ABANDONMENT - NO USE STATEMENT FILED
Tuesday, January 5, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 4, 2021EXTENSION 5 GRANTED
Tuesday, December 8, 2020EXTENSION 5 FILED
Monday, December 21, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, December 8, 2020TEAS EXTENSION RECEIVED
Wednesday, June 10, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 8, 2020EXTENSION 4 GRANTED
Monday, June 8, 2020EXTENSION 4 FILED
Monday, June 8, 2020TEAS EXTENSION RECEIVED
Thursday, October 17, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 15, 2019EXTENSION 3 GRANTED
Tuesday, October 15, 2019EXTENSION 3 FILED
Tuesday, October 15, 2019TEAS EXTENSION RECEIVED
Wednesday, May 22, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, May 24, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 22, 2019EXTENSION 2 GRANTED
Wednesday, May 22, 2019EXTENSION 2 FILED
Wednesday, May 22, 2019TEAS EXTENSION RECEIVED
Thursday, January 17, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, January 17, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, December 21, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 19, 2018EXTENSION 1 GRANTED
Wednesday, December 19, 2018EXTENSION 1 FILED
Wednesday, December 19, 2018TEAS EXTENSION RECEIVED
Tuesday, June 19, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 24, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 24, 2018PUBLISHED FOR OPPOSITION
Wednesday, April 4, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, March 22, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, March 22, 2018ASSIGNED TO EXAMINER
Tuesday, January 16, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Wednesday, January 3, 2018NEW APPLICATION ENTERED IN TRAM